Robbins LLP Informs Investors of Boston Scientific Corporation Class Action Lawsuit

Lawsuit alleges Boston Scientific misled investors about projected revenue and growth

Published on Mar. 6, 2026

Got story updates? Submit your updates here. ›

Robbins LLP has filed a class action lawsuit on behalf of investors who purchased Boston Scientific Corporation (NYSE: BSX) common stock between July 23, 2025 and February 3, 2026. The lawsuit alleges that Boston Scientific misled investors about the company's projected revenue outlook and growth potential, failing to disclose increased competition that was limiting the company's growth.

Why it matters

Boston Scientific is a major medical device company, and allegations of misleading investors about its financial performance and growth prospects could have significant implications for the company and its shareholders. The class action lawsuit seeks to recover losses for affected investors.

The details

According to the complaint, Boston Scientific created the false impression that it had reliable information about its projected revenue and growth, while minimizing risks from competition and macroeconomic factors. However, the company was allegedly experiencing new competition that was limiting its U.S. Electrophysiology market share and growth potential. On February 4, 2026, Boston Scientific announced disappointing Q4 2025 results and weak guidance for 2026, causing the stock price to decline over 17%.

  • The class period is from July 23, 2025 to February 3, 2026.
  • On February 4, 2026, Boston Scientific announced Q4 2025 results and 2026 guidance that disappointed investors.

The players

Boston Scientific Corporation

A global medical device company that develops, manufactures, and markets devices used across various specialties.

Robbins LLP

A law firm representing the plaintiffs in the class action lawsuit against Boston Scientific Corporation.

Got photos? Submit your photos here. ›

What’s next

The lead plaintiff in the class action lawsuit will be determined, and the case will proceed through the legal process.

The takeaway

This case highlights the importance of transparency and accurate financial reporting by public companies. Investors rely on this information to make informed decisions, and allegations of misleading statements can have serious consequences for a company and its shareholders.